Contineum Therapeutics, Inc.
CTNMHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in. With a market capitalization of $532.0M, it sits in small-cap territory. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Market Cap
$532.0M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-7.84
EPS (TTM)
$-1.97
EPS (Fwd)
$-1.81
ROE
-26.9%
ROA
-18.2%
Cash
$246.3M
Total Debt
$7.0M
Free CF
-$39.0M
52W Change
227.1%
Annual Financials
Cash vs Debt
With $246.3M in cash and $7.0M in debt, CTNM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$39.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, CTNM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Contineum Therapeutics, Inc. and its sector.